Lin BioScience (ROCO:6696) Total Equity: NT$25,134.50 Mil (As of Dec. 2025)

Author: Vera Yuan Vera Yuan
Vera Yuan
Vera Yuan
Director of Data and Quant Analytics at GuruFocus
Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Reviewed by: Charlie Tian Charlie Tian
Charlie Tian
Charlie Tian
Founder & CEO of GuruFocus
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.

ROCO:6696 Lin BioScience Inc ROCO:6696
26 GF Score
Price NT$698.00
! 3 Warning Signs
View Full Analysis

What is Lin BioScience Total Equity?

Lin BioScience ROCO:6696 -6.18% 26 Total Equity is NT$25,134.50 Mil as of Dec. 2025. GuruFocus rates ROCO:6696 with a GF Score™ of 26/100. The stock has 3 warning signs investors should review.

Lin BioScience's total equity for the quarter that ended in Dec. 2025 was NT$25,134.50 Mil.

This is Residual interest, including minority interest, that remains in the assets of the enterprise after deducting its liabilities. Equity is increased by owners’ investments and by comprehensive income, and it is reduced by distributions to the owners.

Lin BioScience Total Equity Historical Data

* Premium members only.

The historical data trend for Lin BioScience's Total Equity can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Lin BioScience Total Equity Chart

Lin BioScience Annual Data
Trend Dec16 Dec17 Dec18 Dec19 Dec20 Dec21 Dec22 Dec23 Dec24 Dec25
Total Equity
Get a 7-Day Free Trial Premium Member Only Premium Member Only 452.98 1,736.02 3,428.99 5,353.84 25,134.50

Lin BioScience Semi-Annual Data
Dec16 Jun17 Dec17 Jun18 Dec18 Jun19 Dec19 Jun20 Dec20 Jun21 Dec21 Jun22 Dec22 Jun23 Dec23 Jun24 Dec24 Jun25 Dec25
Total Equity Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 3,428.99 4,352.63 5,353.84 5,346.85 25,134.50
ROCO:6696
26GF Score
Lin BioScience Inc ROCO:6696
Total Equity is just one metric. See GF Score™, valuation, warning signs, and more.
View Full Analysis

Lin BioScience Total Equity Calculation

Total Equity and Total Liabilities are the two components for Total Assets.

Lin BioScience's Total Equity for the fiscal year that ended in Dec. 2025 is calculated as

Total Equity=Total Assets(Q: Dec. 2025 )-Total Liabilities(Q: Dec. 2025 )
=25425.74-291.242
=25,134.50

Lin BioScience's Total Equity for the quarter that ended in Dec. 2025 is calculated as

Total Equity=Total Assets(Q: Dec. 2025 )-Total Liabilities(Q: Dec. 2025 )
=25425.74-291.242
=25,134.50

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Frequently Asked Questions Learn more about Total Equity →
What does a Total Equity of NT$25,134.50 Mil mean?
Lin BioScience (ROCO:6696) has a Total Equity of NT$25,134.50 Mil as of Dec. 2025. The total amount of equity as record on a company's balance sheet. View historical data for Lin BioScience and its competitors.
Is Lin BioScience's Total Equity too high?
Lin BioScience's current Total Equity is NT$25,134.50 Mil. Overall, Lin BioScience has a GF Score™ of 26/100, reflecting its overall financial health beyond just this single metric.
How does Lin BioScience's Total Equity compare to VRTX and REGN?
Lin BioScience's Total Equity of NT$25,134.50 Mil can be compared against companies in the Biotechnology industry. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Total Equity for a Biotechnology company?
A good Total Equity depends on the Biotechnology industry context. However, Total Equity should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Total Equity mean?
A high Total Equity can signal that a stock is expensive relative to its fundamentals. The total amount of equity as record on a company's balance sheet. View historical data for Lin BioScience and its competitors. Lin BioScience's current Total Equity is NT$25,134.50 Mil. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Lin BioScience stock overvalued right now?
Lin BioScience (ROCO:6696) has a current Total Equity of NT$25,134.50 Mil. The current Total Equity is NT$25,134.50 Mil. Lin BioScience's overall GF Score™ is 26/100 with 3 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Total Equity calculated?
Total Equity is calculated from a company's financial statements. For Lin BioScience (ROCO:6696), the current Total Equity is NT$25,134.50 Mil as of Dec. 2025. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.

Lin BioScience Business Description

Address Zhongxiao East Road, 12th Floor, No. 68, Section 5, Xinyi District, Taipei City, TWN, 110
Lin BioScience Inc is a drug development company. It specializes in therapies for diseases with unmet medical needs. Its novel pipeline consists of first-in-class drugs aimed at treating life-threatening or disabling diseases in oncology, ophthalmology, cardiovascular, and metabolic disease.
26GF Score

Get the complete analysis for ROCO:6696

Total Equity is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.

NT$698.00
Price